home / stock / mirm / mirm quote
Last: | $43.33 |
---|---|
Change Percent: | -1.56% |
Open: | $41 |
Close: | $43.33 |
High: | $44.6995 |
Low: | $39.7032 |
Volume: | 2,403,489 |
Last Trade Date Time: | 07/26/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$43.33 | $41 | $43.33 | $44.6995 | $39.7032 | 2,403,489 | 07-26-2024 |
$40.37 | $39.4 | $40.37 | $41.88 | $38.91 | 800,111 | 07-25-2024 |
$39.07 | $39.88 | $39.07 | $40.44 | $39.07 | 286,012 | 07-24-2024 |
$40.2 | $39.53 | $40.2 | $40.75 | $39.53 | 482,855 | 07-23-2024 |
$39.53 | $39.69 | $39.53 | $39.93 | $38.675 | 618,082 | 07-22-2024 |
$39.49 | $37.46 | $39.49 | $40.07 | $37.44 | 1,224,991 | 07-19-2024 |
$37.37 | $38.13 | $37.37 | $38.985 | $37.07 | 471,304 | 07-18-2024 |
$38.37 | $39.58 | $38.37 | $40.38 | $37.92 | 714,140 | 07-17-2024 |
$40 | $39.63 | $40 | $40.36 | $39.46 | 975,252 | 07-16-2024 |
$39.48 | $39.51 | $39.48 | $40.37 | $39.22 | 796,320 | 07-15-2024 |
$39.44 | $37.8 | $39.44 | $39.9 | $37.38 | 1,072,100 | 07-12-2024 |
$37.66 | $36.61 | $37.66 | $37.9 | $36.17 | 758,885 | 07-11-2024 |
$35.92 | $36.7 | $35.92 | $36.79 | $35.63 | 422,525 | 07-10-2024 |
$36.6 | $36.13 | $36.6 | $36.92 | $35.11 | 561,983 | 07-09-2024 |
$35.91 | $34.65 | $35.91 | $36.635 | $34.47 | 1,009,029 | 07-08-2024 |
$34.43 | $33.74 | $34.43 | $34.5 | $33.64 | 593,804 | 07-05-2024 |
$33.88 | $33.76 | $33.88 | $34.525 | $33.515 | 222,124 | 07-04-2024 |
$33.88 | $33.76 | $33.88 | $34.525 | $33.515 | 222,124 | 07-03-2024 |
$33.68 | $34.18 | $33.68 | $34.52 | $33.45 | 385,234 | 07-02-2024 |
$34.16 | $34.43 | $34.16 | $35.44 | $34.065 | 693,198 | 07-01-2024 |
News, Short Squeeze, Breakout and More Instantly...
Mirum Pharmaceuticals Inc. Company Name:
MIRM Stock Symbol:
NASDAQ Market:
Mirum Pharmaceuticals Inc. Website:
Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that the U.S. Food and Drug Administration (FDA) has approved a label expansion for LIVMARLI® (maralixibat) oral solution for the treatment of cholestatic pruritus in patients with progressive familial intrahepatic cholestasis (PFIC)...
European Commission grants LIVMARLI marketing authorization for treatment of PFIC in patients three months and older. Approval follows positive opinion from CHMP concluding LIVMARLI’s clinical benefit over existing therapy in PFIC. LIVMARLI also received positive COMP opinion recom...
Submission based on the positive Phase 3 RESTORE study Mirum holds orphan designation for chenodiol in CTX Potential to have first and only therapy indicated for CTX in the US Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced the submission of a new drug application (ND...